… versus abiraterone in patients with chemotherapy-… abiraterone are likely to be used more
frequently in earlier disease settings, including hormone-sensitive metastatic prostate cancer…

… question 3 (ie, worst pain in the past 24 h). Patients with previous chemotherapy for prostate
cancer (unless administered in an adjuvant or neoadjuvant setting), or previously treated …

… either enzalutamide or abiraterone without any sequential … to abiraterone and vice versa;
(3) those who switched from first-line enzalutamide or abiraterone to second-line chemotherapy…

… While in registration studies no effect of previous chemotherapy on abiraterone exposure
was observed, a similar trend towards higher exposure in less pretreated patients was found in …

… (abiraterone or enzalutamide) or taxane-based chemotherapy. … plus abiraterone versus
placebo plus abiraterone have … effect with olaparib plus abiraterone that is irrespective of HRRm …

… setting of metastatic castration-resistant prostate cancer (mCRPC) mainly comprise next-generation
hormonal agents (eg, abiraterone and enzalutamide) or docetaxel chemotherapy. …

… -ADT setting, abiraterone acetate plus prednisone significantly … without prior chemotherapy.
It also delayed clinical decline, time to cytotoxic chemotherapy, time to opiate use for cancer …

… COU-AA-302 pre-chemotherapy was 11.1 months.3, … no prior Docetaxel 9.8 months and
with prior Docetaxel 4.4 months, respectively). Within the PREVAIL trial of ENZ in chemotherapy-…

… The study was practically designed with prior chemotherapy and use of novel hormonal
agents allowed in the mCSPC or nmCRPC settings. Patients were allowed to receive up to 4 …

… Our results, therefore, highlight the value of abiraterone not only in … recent data from the
large Canadian real-world Canadian Observational Study in Metastatic Cancer of the Prostate …